FDA: Scientific Progress Still Needed To Support Cosmetic Animal Testing Ban
The US FDA is highly engaged in the areas of predictive toxicology and alternative methods to phase out cosmetic animal testing, including evaluation of a 3D-bioprinted human skin model for in vitro permeation testing. However, continued progress is “critically needed” to make feasible the ban on cosmetic animal testing envisioned by US lawmakers, agency leadership suggests.
You may also be interested in...
The FDA’s cosmetics office is exploring integrated testing strategies to identify potential skin sensitizers without use of animals, as well as use of in vitro assays to evaluate cosmetic ingredients’ dermal penetration potential. Meanwhile, CFSAN is testing the effects of substances on gene expression in collaboration with other federal agencies as part of Tox21-Phase III.
Independent Beauty Association president Ken Marenus discusses the trade group’s vision for modern, proportionate cosmetics regulation and forces at work that could undermine progress and endanger small businesses.
Researchers testing OTCs, supplements and cosmetics seek in vitro test alternatives as animal toxicity tests aren’t strong indicators for humans, says consultant John Harbell. At CHPA conference, he says half of drug failures in clinical trials are due to toxicity in humans despite animal tests showing safety.